Search

Invokana

Invokana

canagliflozin

Manufacturer:

Janssen-Cilag

Distributor:

DKSH
NEW Brand Resources
Concise Prescribing Info
Contents
Canagliflozin
Indications/Uses
Monotherapy & combination therapy as an adjunct to diet & exercise to improve glycemic control in adults w/ type 2 DM. To reduce the risk of major adverse CV events (CV death, nonfatal MI & stroke) in adults w/ type 2 DM who have established CV disease or at least 2 risk factors for CVD.
Click to view Invokana detailed prescribing information
Dosage/Direction for Use
Adult ≥18 yr 100 mg or 300 mg once daily. Patient w/ eGFR ≥60 mL/min/1.73 m2 (CrCl ≥60 mL/min) Consider 300 mg once daily, eGFR 45-<60 mL/min/1.73 m2 (CrCl 45-<60 mL/min) 100 mg once daily. Patient on loop diuretic & elderly ≥75 yr Initially 100 mg once daily, may be increased to 300 mg if initial dose is tolerated & tighter glycemic control is needed.
Click to view Invokana detailed prescribing information
Administration
Should be taken on an empty stomach: Preferably taken before the 1st meal of the day. Swallow whole.
Contraindications
Hypersensitivity.
Click to view Invokana detailed prescribing information
Warnings
For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Invokana detailed prescribing information
Special Precautions
Not to be used for type 1 diabetes & diabetic ketoacidosis. Risk of lower limb (mainly toes) amputation. Present or history of serious heart disease or stroke; hypotension. Concomitant use w/ antihypertensives & diuretics. Regularly check feet for wounds, discolouration, pain/tenderness & ensure foot care & adequate hydration. Test for kidney function prior to & during treatment. False positive result for urine glucose. Patients w/ lactose intolerance. Patients w/ severe kidney/liver problems or those on dialysis. Increased risk of hypoglycaemia w/ other antidiabetics. Dizziness or lightheadedness may occur which may affect the ability to drive, cycle, or use tools or machines. Not to be used during pregnancy & lactation. Not recommended for childn & adolescents <18 yr.
Click to view Invokana detailed prescribing information
Adverse Reactions
Hypoglycaemia; vag yeast infection. Rash/redness of the penis or foreskin (yeast infection); UTI; changes in urination (eg, frequent or large amounts of urination, urgent need to urinate & at night); constipation; feeling thirsty; nausea; possible changes in blood cholesterol levels & increases in haematocrit.
Drug Interactions
Hypoglycaemia w/ other antidiabetics eg, insulin or sulphonylurea (eg, glimepiride or glipizide). May lower BP w/ antihypertensives eg, diuretics. St. John's wort; carbamazepine, phenytoin, or phenobarb; efavirenz or ritonavir; rifampicin; cholestyramine; digoxin or digitoxin; dabigatran.
Click to view Invokana detailed prescribing information
Storage
View Invokana storage conditions for details to ensure optimal shelf-life.
Description
View Invokana description for details of the chemical structure and excipients (inactive components).
Action
View Invokana mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BK02 - canagliflozin ; Belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Invokana FC tab 100 mg
Packing/Price
3 × 10's
Form
Invokana FC tab 300 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in